Roberts v. the Future: Genetic Screening and the Future of Personal Autonomy
By New York Times,
New York Times
| 08. 28. 2005
III. Genetic Screening and the Future of Personal Autonomy
Every Supreme Court confirmation hearing since the election of Ronald Reagan has been marked by efforts -- nearly always unsuccessful -- to predict the nominee's views on Roe v. Wade. The Roberts hearings are unlikely to prove an exception. If Roberts is confirmed, he will have two opportunities in the next Supreme Court term to reveal some of his views about the potential implications of Roe -- in one case involving a teen-health exception in parental-notification laws and in another concerning the federal power to prosecute protesters at abortion clinics. Regardless of whether Roe v. Wade remains on the books in 10 or 20 years, however, America's political and legal disputes about reproduction may well have moved far beyond efforts to balance the interests of a fetus against the interests of a pregnant mother. Instead, the country will most likely be debating the use of sophisticated technologies involving genetic manipulation and reproductive cloning outside the womb -- controversial procedures that may prompt restrictions or bans by state legislatures or Congress. In...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...